18. December 2023 | Corporate News

Marinomed Biotech AG evaluates strategic options for Carragelose portfolio

  • Marinomed evaluates strategic options for Carragelose business and hires advisor to approach potential partners
  • Change in regulatory legislation for medical devices creates favourable market environment for Carragelose product portfolio
  • Marinomed to focus on core competencies of research and development and generation of intellectual property (IP)

The full press release is available as download here:

Marinomed Biotech AG evaluates strategic options for Carragelose portfolio
(68 KB)